Andrew John Armstrong, MD

Associate Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Associate Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address andrew.armstrong@duke.edu

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996

Publications

Sonpavde, G, Pond, GR, Templeton, AJ, Fandi, A, Tombal, B, Rosenthal, M, Armstrong, AJ, and Petrylak, DP. "Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel." European urology 69, no. 6 (June 2016): 980-983.

PMID
26497922
Scholars@Duke

Penson, DF, Armstrong, AJ, Concepcion, R, Agarwal, N, Olsson, C, Karsh, L, Dunshee, C, Wang, F, Wu, K, Krivoshik, A, Phung, D, and Higano, CS. "Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 18 (June 2016): 2098-2106.

PMID
26811535
Scholars@Duke

Zhang, T, Boominathan, R, Foulk, B, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, Hsu, DS, Healy, P, Li, J, Pi, C, Prendergast, KM, Hobbs, C, Gemberling, S, George, DJ, Hurwitz, HI, Connelly, M, Garcia-Blanco, MA, and Armstrong, AJ. "Development of a Novel c-MET-Based CTC Detection Platform." Molecular cancer research : MCR 14, no. 6 (June 2016): 539-547.

PMID
26951228
Scholars@Duke

Antonarakis, ES, Armstrong, AJ, Dehm, SM, and Luo, J. "Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting." Prostate cancer and prostatic diseases (May 17, 2016). (Review)

PMID
27184811
Scholars@Duke

Halabi, S, Kelly, WK, Ma, H, Zhou, H, Solomon, NC, Fizazi, K, Tangen, CM, Rosenthal, M, Petrylak, DP, Hussain, M, Vogelzang, NJ, Thompson, IM, Chi, KN, de Bono, J, Armstrong, AJ, Eisenberger, MA, Fandi, A, Li, S, Araujo, JC, Logothetis, CJ, Quinn, DI, Morris, MJ, Higano, CS, Tannock, IF, and Small, EJ. "Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 14 (May 2016): 1652-1659.

PMID
26951312
Scholars@Duke

Scher, HI, Morris, MJ, Stadler, WM, Higano, C, Basch, E, Fizazi, K, Antonarakis, ES, Beer, TM, Carducci, MA, Chi, KN, Corn, PG, de Bono, JS, Dreicer, R, George, DJ, Heath, EI, Hussain, M, Kelly, WK, Liu, G, Logothetis, C, Nanus, D, Stein, MN, Rathkopf, DE, Slovin, SF, Ryan, CJ, Sartor, O, Small, EJ, Smith, MR, Sternberg, CN, Taplin, ME, Wilding, G, Nelson, PS, Schwartz, LH, Halabi, S, Kantoff, PW, and Armstrong, AJ. "Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 12 (April 2016): 1402-1418.

PMID
26903579
Scholars@Duke

Evans, CP, Higano, CS, Keane, T, Andriole, G, Saad, F, Iversen, P, Miller, K, Kim, CS, Kimura, G, Armstrong, AJ, Sternberg, CN, Loriot, Y, de Bono, J, Noonberg, SB, Mansbach, H, Bhattacharya, S, Perabo, F, Beer, TM, and Tombal, B. "The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer." European urology (March 19, 2016).

PMID
27006332
Scholars@Duke

Armstrong, AJ, Halabi, S, Healy, P, Lee, WR, Koontz, BF, Moul, JW, Mundy, K, Creel, P, Wood, S, Davis, K, Carducci, MA, Stein, M, Hobbs, C, Reimer, B, Nguyen, M, Anand, M, Bratt, L, Kim, S, Tran, PT, and George, DJ. "A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy." March 2016.

PMID
26754260
Scholars@Duke

Armstrong, AJ, Healy, P, Halabi, S, Vollmer, R, Lark, A, Kemeny, G, Ware, K, and Freedland, SJ. "Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer." Prostate cancer and prostatic diseases 19, no. 1 (March 2016): 40-45.

PMID
26458958
Scholars@Duke

Armstrong, AJ, Halabi, S, Eisen, T, Broderick, S, Stadler, WM, Jones, RJ, Garcia, JA, Vaishampayan, UN, Picus, J, Hawkins, RE, Hainsworth, JD, Kollmannsberger, CK, Logan, TF, Puzanov, I, Pickering, LM, Ryan, CW, Protheroe, A, Lusk, CM, Oberg, S, and George, DJ. "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial." The Lancet. Oncology 17, no. 3 (March 2016): 378-388.

PMID
26794930
Scholars@Duke

Pages